Biotech resilient in Q3

Despite the dismal economic climate, biotech stocks, financing, acquisitions and partnerships remained relatively solid. Although biotech indices have climbed only slightly since the beginning of 3Q07, they have performed much better than the broader indices, which plunged. Large bids to acquire Genentech (S. San Francisco, CA, USA) and ImClone (New York) also generated interest in the sector. Financing is unlikely to outstrip the $53 billion high in 2007, but last quarter actually managed to improve over a recent low in 2Q08.

Biotech stock market performance

Global biotech industry financing

Venture capital

Global biotech venture capital investment

Global biotech initial public offerings

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lawrence, S. Biotech resilient in Q3. Nat Biotechnol 26, 1212 (2008). https://doi.org/10.1038/nbt1108-1212

Download citation

Further reading